Translation



PCT



531,980

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference					
54062	FOR FURTHER ACTI	ION	See Form PCT/IPEA/416		
International application No. International filin			Priority date (day/month/year)		
PCT/EP2003/012773 14 November 20		(14.11.2003)	15 November 2002 (15.11.2002)		
International Patent Classification (IPC) or n C07D 487/04	ational classification and II	PC			
Applicant .	BASF AKTIENGES	SELLSCHAFT			
This report is the international preling Authority under Article 35 and trans	ninary examination report, mitted to the applicant acc	established by this ording to Article 3	s International Preliminary Examining 6.		
2. This REPORT consists of a total of	6 sheets, inc	cluding this cover	sheet.		
3. This report is also accompanied by A					
a. (sent to the applicant and	to the International Burea	nu) a total of	sheets, as follows:		
and/or sheets con	sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).				
sheets which sup- beyond the discle Supplemental Bo	sure in the international ap	hich this Authorit	y considers contain an amendment that goes as indicated in item 4 of Box No. I and the		
b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) , containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the					
Administrative Instruction	ns).				
4. This report contains indications rela	ting to the following items	:			
Box No. I Basis of the re	port				
Box No. II Priority		•			
Box No. III Non-establish	ment of opinion with regar	d to novelty, inven	tive step and industrial applicability		
Box No. IV Lack of unity					
Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
Box No. VI Certain docum	nents cited				
Box No. VII Certain defect	s in the international applic	cation			
Box No. VIII Certain observations on the international application					
Date of submission of the demand	D	Date of completion	of this report		
28 April 2004 (28.04.2004)		11 F	ebruary 2005 (11.02.2005)		
Name and mailing address of the IPEA/EP	А	authorized officer			
Facsimile No.	Т	elephone No.			



INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

Int	onal application No.
F	CT/EP2003/012773

Box No.	1	Basis of the report			
1. With regard to the language, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.					
	This report is based on translations from the original language into the following language, which is language of a translation furnished for the purpose of:				
		international search (under Rules 12.3 and 23.1(b))			
ļ		publication of the international application (under Rule 12.4)			
		international preliminary examination (under Rules 55.2 and/or 55.3)			
furnis	shed t ere no	rd to the elements of the international application, this report is based on (replacement sheets which have been to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" it annexed to this report):			
		international application as originally filed/furnished			
	page	description: 1-31 as originally filed/furnished			
	page				
	page				
	the c	claims:			
	page	, we originally modification			
	page	se*			
	page				
	the d	drawings:			
''	page				
	page	, as originary mountainsing			
	page				
1 🗂	2 506				
"	4 300	quence listing and/or any related table(s) – see Supplemental Box Relating to Sequence Listing.			
3.	The	amendments have resulted in the cancellation of:			
]3. [_]	1116				
	님	the description, pages			
j	님	the claims, Nos.			
		the drawings, sheets/figs			
1		the sequence listing (specify):			
		any table(s) related to sequence listing (specify):			
4.	mad	report has been established as if (some of) the amendments annexed to this report and listed below had not been e, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box to 70.2(c)). the description, pages the claims, Nos the drawings, sheets/figs			
1	H	the sequence listing (specify):			
	H	any table(s) related to sequence listing (specify):			
	لــا	any table(s) related to sequence fixing (specify):			
* If iter	n 4 ap	oplies, some or all of those sheets may be marked "superseded."			

International	application No.	
PCT, P	03/12773	

v.	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1.	Statement			
	Novelty (N)	Claims	1-10	YES
		Claims	· ·	NO NO
	Inventive step (IS)	Claims		YES
		Claims	1-10	NO
	Industrial applicability (IA)	Claims	1-10	YES
		Claims		NO

2. Citations and explanations

Reference is made to the following documents:

D1: DE 101 21 102 A (BAYER AG) 7 November 2002

(2002-11-07) mentioned in the application

D2: EP-A-0 550 113 (SHELL INT RESEARCH) 7 July 1993

(1993-07-07) mentioned in the application

1. Novelty

The present application discloses triazolopyrimidines of the general formula I (claims 1 to 4), a method for the production thereof (5 to 8), an agent for the control of harmful fungi containing a compound of formula I (claim 9) and a method for the control of harmful fungi using a compound of formula I (claim 10).

D1 and D2 disclose triazolopyrimidine derivatives which differ from the compounds according to the invention by virtue of the mercapto group in the 2-position of the triazolopyrimidine skeleton. The D1 and D2 compounds are suitable for the control of harmful fungi.

The subject matter of the present application is considered novel (PCT Article 33(2)).

2. Inventive step

The problem addressed by the invention was to produce further triazolopyrimidine derivatives having enhanced efficacy against harmful fungi by comparison with the known compounds (page 3, lines 14 and 15).

D1, which is considered to be the closest prior art, discloses triazolopyrimidines of the general formula (I) from which the subject matter of claim 1 differs in that a mercapto group is present in the 2-position of the triazolopyrimidine skeleton and the D1 compounds have an alkylthio group in the 2-position. The D1 compounds are used for the control of micro-organisms.

The solution to the above-mentioned problem lies in the production of compounds defined by the general formula I in claim 1. The data for efficacy against harmful fungi is given for a compound from example 9 in the last paragraph on page 31.

The structural difference between the present compounds in claim 1 and the prior art compounds in D1 is not very great. The compounds in the present application have an HS group in the 2-position, whereas the closest compounds in table 1 of D1 have a CH₃S group in the 2-position. The problem addressed by the invention was to provide compounds with enhanced activity. Sufficient comparative data was not, however, found in the description in the present application to demonstrate that the compounds in claim 1 exhibit enhanced activity over the D1 compounds.

Furthermore, the application does not contain sufficient information credibly to demonstrate that not only the

above-mentioned compound from example 9 but also a further group of compounds more representative of the whole scope actually constitute a solution to the above-mentioned problem. An inventive step cannot be acknowledged owing to the above-mentioned defects (PCT Article 33(3)).

3. Clarity

The applicant is advised that the substituent R_3 is not defined either in formula III of claim 6 or in the description (page 3, line 27 to page 4, line 5).

It has also been established that claims 2 and 3 do not correspond to preferred embodiments. Inconsistencies between the description and the claims should be avoided if they may give rise to doubts as to the scope of protection.

An obvious error has been found in line 3 on page 4 of the description. The substituent R is defined in parentheses instead of R_4 .

A further obvious error has been found in line 13 on page 14 of the description. The substituent L_n is defined instead of L_m .